

For further information contact:
Richard J. Freer, Ph.D.
Chairman & COO
Commonwealth Biotechnologies, Inc.
804-648-3820

Senior Vice President of Genzyme Pharmaceuticals joins CBI Board

RICHMOND, VIRGINIA (March 23, 2007) – Commonwealth Biotechnologies, Inc. (“CBI”) (Nasdaq Capital Market: CBTE) is pleased to announce that the Senior Vice President and General Manager of Genzyme Pharmaceuticals, Mr. Daniel O. Hayden, has been appointed as a non-executive Director of CBI. Mr. Hayden has over 35 years experience in the pharmaceutical and biotechnology industries, the last 8 of which he has served in senior executive roles with Genzyme Pharmaceuticals, a business unit of Genzyme Corporation. Mr. Hayden has well documented achievements in global business management, strategic planning, new business development and strategic alliance partnering.

“Mr. Hayden brings to CBI a wealth of experience in the drug development market and major networks in the biotechnology and pharmaceutical industries,” said Dr Paul D’Sylva, CEO of Commonwealth Biotechnologies. “Mr. Hayden’s experience will help create new opportunities for our products and services and add significant momentum to CBI’s growth in 2007 and beyond,” he added.

“I am delighted to join the board of CBI,” said Mr. Hayden. “With the recent addition of new management and a new strategic direction, I believe that CBI is in a strong position to become a major force in the drug discovery outsourcing market and I look forward to playing a role in the future success of CBI.”

About CBI

CBI specializes in life sciences R&D outsourcing and offers cutting-edge expertise and a complete array of the most current synthetic and analytical technologies in the areas of bio-

defense, laboratory support and contract research. CBI is well positioned to compete in the global market for drug discovery outsourcing with an experienced management team and highly trained scientific staff located in a world-class laboratory in Richmond, Virginia. For more information visit www.cbi-biotech.com.

About Mimotopes

Mimotopes Pty Ltd, a wholly owned subsidiary of CBI, is a global leader in high quality research-grade peptide products and applications for the drug discovery industry. Mimotopes' patented synthesis technologies, state-of-the-art facilities and highly experienced staff make it one of the leading research grade peptide synthesis companies in the world. In 2006, Mimotopes developed significant partnerships with key life science companies Invitrogen and Genzyme. For more information visit www.mimotopes.com. For information on the Mimotopes - Genzyme Pharmaceuticals strategic alliance visit www.peptidechain.com

Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in CBI's filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. No statement herein should be considered an offer of any securities. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. Specifically, there can be no guarantee that Mr. Hayden's appointment will result in additional contract signings or revenues for CBI. A number of factors, including customer demand, industry trends, armed conflict, and terrorist activities could alter trends referenced herein. CBI undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.